Shionogi Completes $2 Billion IntraBio Acquisition

Shionogi has completed its $2 billion acquisition of IntraBio, adding Aqneursa (levacetylleucine) to its rare disease portfolio. Under the agreement announced October 5, 2026, Shionogi’s New Jersey-based subsidiary paid the amount in a lump sum for all outstanding IntraBio shares, gaining global intellectual property and commercialization rights to the drug.

The FDA approved Aqneursa in 2024 for neurological manifestations of Niemann-Pick disease type C in adults and children weighing at least 15 kg. In Europe, the drug was approved in January 2026 for the same condition in patients aged 6 years and older who weigh at least 20 kg, either in combination with miglustat or alone if miglustat is not tolerated.

In September 2026, the FDA also approved Aqneursa to treat ataxia in adults and children diagnosed with ataxia-telangiectasia who weigh at least 15 kg, making it the first FDA-approved treatment for ataxia in this population. The European Medicines Agency is reviewing the drug for adults and children with ataxia-telangiectasia, a rare inherited disorder that progressively affects movement and coordination.

Aqneursa is also being evaluated for CACNA1A disorders in a randomized, double-blind, placebo-controlled Phase 3 crossover study. Shionogi said it will continue the programs initiated by IntraBio and explore whether to study Aqneursa in other rare diseases.

The deal follows Shionogi’s acquisition of Radicava ORS (edaravone), a treatment for amyotrophic lateral sclerosis. The company’s rare disease pipeline includes clinical programs in Pompe disease, fragile X syndrome and Jordan’s syndrome, as well as early-stage programs for other rare neurodegenerative diseases.

Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!

Sign up now!

  • <<
  • >>

Join the Discussion